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Abstract
Background: Sepsis and systemic-inflammatory-response-syndrome (SIRS) remain major causes for fatalities on intensive
care units despite up-to-date therapy. It is well accepted that stem cells have immunomodulatory properties during
inflammation and sepsis, including the activation of regulatory T cells and the attenuation of distant organ damage.
Evidence from recent work suggests that these properties may not be exclusively attributed to stem cells. This study was
designed to evaluate the immunomodulatory potency of cellular treatment during acute inflammation in a model of
sublethal endotoxemia and to investigate the hypothesis that immunomodulations by cellular treatment during
inflammatory response is not stem cell specific.
Methodology/Principal Findings: Endotoxemia was induced via intra-peritoneal injection of lipopolysaccharide (LPS) in
wild type mice (C3H/HeN). Mice were treated with either vital or homogenized amniotic fluid stem cells (AFS) and sacrificed
for specimen collection 24 h after LPS injection. Endpoints were plasma cytokine levels (BD
TM Cytometric Bead Arrays), T cell
subpopulations (flow-cytometry) and pulmonary neutrophil influx (immunohistochemistry). To define stem cell specific
effects, treatment with either vital or homogenized human-embryonic-kidney-cells (HEK) was investigated in a second
subset of experiments. Mice treated with homogenized AFS cells showed significantly increased percentages of regulatory T
cells and Interleukin-2 as well as decreased amounts of pulmonary neutrophils compared to saline-treated controls. These
results could be reproduced in mice treated with vital HEK cells. No further differences were observed between plasma
cytokine levels of endotoxemic mice.
Conclusions/Significance: The results revealed that both AFS and HEK cells modulate cellular immune response and distant
organ damage during sublethal endotoxemia. The observed effects support the hypothesis, that immunomodulations are
not exclusive attributes of stem cells.
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Introduction
Endotoxemia, the presence of bacteria in the blood, can lead to
sepsis and subsequent multiple organ dysfunction syndrome due to
uncontrolled activation of the innate immune system and a
resulting fulminant inflammatory cascade. Despite modern
intensive care medicine with multimodal therapy including
immunomodulatory agents, sepsis remains a major cause of death
on intensive care units [1].
Stem cells of various origins have been widely investigated for
their therapeutic potential during the last decades. Promising
results from in vitro and in vivo studies resulted in a large number of
clinical trials and experimental clinical applications (i.e. autoim-
mune diseases, neurodegenerative diseases, spinal trauma, cere-
brovascular disease, cardiovascular diseases, degenerative liver
disease, cancer, tissue engineering) [2,3]. More recently, the
experimental therapeutic application of stem cells during inflam-
mation and sepsis introduced new potential strategies for critical
care medicine. It is now widely accepted that stem cells provide
immunomodulatory properties during inflammation and sepsis.
The majority of therapeutic stem cell studies revealed anti-
inflammatory immunomodulations resulting in decreased organ
damage and increased survival [4,5,6]. The observed immuno-
modulations include suppression of T-lymphocytes (CD4
+ and
CD8
+) but also induction of regulatory T cells (Tregs) [7,8], which
in turn have been reported to decrease distant organ damage [9].
However, the exact molecular backgrounds of these phenomena
remain unclear and several species dependent differences have
been recognized: Whereas enhancing the immunosuppressive
effect of human mesenchymal stem cells (MSCs) has been reported
to be mainly dependent on soluble factors, rodent MSCs require
cell-to-cell contact of viable cells [7,8,10].
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rapidly senescence [11]. Moreover, the application of MSCs may
bare some risks (including malignant tumor formation) and the
discussion about potential therapeutic values is controversial
[12,13].
The isolation of pluripotent stem cells from amniotic fluid (AFS
cells) by selection for expression of the membrane stem cell factor
receptor c-Kit, revealed a new and safe source of cells that could
have a therapeutic value in various diseases prenatally and/or
postnatally [14]. AFS cells are easy to isolate and in contrast to
MSCs, to expand and to be genetically manipulated [15,16]
Subsequently, the potential of AFS cell treatment has been
investigated in a rat model of necrotizing enterocolitis (NEC), a
severe septic condition of ischemic and inflammatory nature in
mostly premature infants. Zani et al. reported increased survival,
decreased incidence of NEC together with decreased bowel
damage after intraperitoneal injection of AFS cells [17]. It is
however unclear whether in that model of disease AFS cells do
mediate the immunological response.
The exclusive role of stem cell triggered immunomodulation has
been recently questioned, showing that mature stromal cells of
various origins provide a powerful immunomodulation compara-
ble if not superior to stem cells [18]. Moreover, very recently it has
been shown that AFS cells may be able to suppress inflammatory
responses in vitro via a paracrine/soluble factors pathway [19].
However, the role of AFS cell treatment during in vivo
inflammatory response remains unclear.
The present study was designed to investigate the modulation of
inflammatory response to lipopolysaccharide (LPS) endotoxemia
by cellular treatment with AFS cells. To evaluate if possible
immunomodulations are dependent on cell viability either vital or
homogenized AFS cells were administered. In a second subset of
experiments, human-embryonic-kidney-cells (HEK [293 T]), a
non-stem cell line of epithelial origin, were administered in the
same model of sublethal endotoxemia to define stem cell specific
effects.
This study was designed to evaluate the hypothesis that
immunomodulations by cellular treatment during inflammatory
response is not stem cell specific.
Materials and Methods
Cell lines
AFS cells. Human AFS cells were received as a generous gift
from Dr de Coppi. They were obtained, characterized and
cultured as previously described [15]. Briefly, cells were collected
from consenting volunteer donors (following guidelines of the
Azienda Ospedaliera Padova [protocol number 451P/32887]) and
selected by CD117 (c-Kit) immunoselection, using Mini-MACS
(Miltenyi Biotec S.r.l., Bologna, Itlay) as previously described
[15,20]. Cells were subcultured routinely at a dilution of 1:4 to 1:8
and expansion ,70% confluence was ensured.
Phenotypic fluorescence activated cell sorter (FACS) analysis of
AFS cells was studied by incubating cells with anti-human
antibodies: CD29 FITC, CD44 FITC, CD73 PE, CD105 PE,
(Beckton Dickinson, Pharmingen, San Jose, CA); HLA-ABC FITC
and HLA-DR PE (Immunotech, Marseille, France). Immunoflu-
orescence of AFS cells in cover slip was performed. Cells were
fixed in paraformaldehyde 4% for 5 minutes. Staining was
performed using c-Kit antibody (Santa Cruz Sc-13508) and
SSEA-4 (Santa Cruz, Biotechnology, CA, USA). Sections were
mounted with 4,6-diamidino-2-phenylindole (Vector Laboratories,
Segrate, Italy) and images were captured with Olympus BX60
microscope (Olympus Italia S.r.l., Segrate, Italy) using Viewfinder
Lite software.
HEK 293 T cells. HEK 293 T is a well characterized,
commercially available cell line of epithelial origin. HEK 293 T
cells were purchased at ATCC, LGC Standards GmbH, Germany
and cultured in Dulbecco’s Modified Eagle Medium (DMEM), 1%
Penicillin/Streptomycin and 5% Fetal Calf Serum. Cells were
subcultured routinely at a dilution of 1:4 to 1:8 and expansion
,70% confluence was ensured.
Ethics statement
All animal studies were performed in accordance with the
guidelines of the Federation of European Laboratory Animal
Science Associations (FELASA) and the Society of Laboratory
Animal Science (SLAS) and were approved by the local Institute
for Laboratory Animal Research (Hannover Medical School) and
the local Ministry of Consumer Protection and Food Safety of
Lower Saxony, Germany (Permit Nr: 339-42502-12-10-0046).
Animals
For all experiments in this study male C3H/HeN wild type
mice (Charles River, Germany), weighing 25–30 g, were used.
Mice have been handled in our animal facility with a room
temperature of 20–24uC, a relative humidity of 5565% and a
light dark cycle of 12 h. Water and pelleted mouse chow (Altromin
1324) was available throughout the study period.
Mouse model of endotoxemia and group distribution
The study design is presented in Figure 1. To induce sublethal
endotoxemia, mice were injected intraperitoneally with LPS (LPS,
Escherichia coli, Serotype 0127:B8, Sigma, 6 mg/kg) dissolved in
phosphate buffered saline (PBS).
Figure 1. Mouse model of sublethal endotoxemia (study
design). Male C3H/HeN mice were randomly assigned to either
application of vital AFS cells (vitAFS), homogenized AFS cells (homAFS)
or saline only (positive-control). Sublethal endotoxemia was induced by
intraperitoneal injection of LPS. Mice distributed to the vitAFS group
received 10
6 vital AFS cells in 0.7 ml sterile phosphate buffered saline
(PBS) intraperitoneally 2 h after LPS challenge. The same amount of
cells and PBS was used for treatment of the homAFS group, but prior to
injection vital cells were disrupted using the Sonopulse cell disperser
(BANDELIN electronic, Berlin, Germany). The positive-control group
received 0.7 ml sterile PBS without cells or disrupted cell material. Mice
were sacrificed 24 h after LPS challenge and blood as well as tissue
specimens were harvested. A group of 6 animals was sacrificed without
any treatment (negative-control) to determine basal cytokine levels, T-
cell subtype populations and lung polymorphonuclear neutrophil
(PMN) infiltration.
doi:10.1371/journal.pone.0035512.g001
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cells (vitAFS), homogenized AFS cells (homAFS) or saline only
(positive-control). Mice distributed to the vitAFS group received
10
6 vital AFS cells in 0.7 ml sterile phosphate buffered saline (PBS)
intraperitoneally 2 h after LPS challenge. The same amount of
cells and PBS was used for treatment of the homAFS group, but
prior to injection vital cells were disrupted by sonication (5 min),
using the Sonopulse cell disperser (BANDELIN electronic, Berlin,
Germany). The positive-control group received 0.7 ml sterile PBS
without cells or disrupted cell material (Figure 2).
Eight hours after LPS injection 6 animals out of each group
were sacrificed to determine acute cytokine response. The
remaining animals (n=18 per group) were sacrificed 24 h after
LPS challenge and blood as well as tissue specimens were
harvested.
To determine stem cell specific effects, a second set of
experiments was performed with vital (vitHEK) as well as
homogenized (homHEK) human embryonic kidney cells (HEK
293 T, ATCC, LGC Standards GmbH, Germany) according to
the same protocol (n=6 per group), which was used for AFS cells.
A group of 6 animals was sacrificed without any treatment
(negative-control) to determine basal cytokine levels, T-cell
subtype populations and lung polymorphonuclear neutrophil
(PMN) infiltration. All animals were clinically observed and
moribund mice were euthanatized immediately.
Sample collection (Plasma, Lymphocytes, Lung tissue)
Mice were anesthetized with 100 mg/kg Ketamine (KetanestH,
Pfizer Pharma, Germany) and 5 mg/kg Xylazine (RompunH,
Bayer, Germany). They were exsanguinated by cardiac puncture.
Heparinized blood was centrifuged (3000 U/min, 5 min, 4uC),
plasma was snap-frozen in liquid nitrogen and stored at 280uC.
Lymphocytes were extracted by straining the spleen through a
mesh. The obtained cells were resuspended in 0.9% sterile saline.
Cells were washed twice with phosphate-buffered saline (PBS),
diluted in 1 mL 0.9% sterile saline and processed for the
evaluation of CD4
+, CD8
+ and CD4+CD25+Foxp3
+ cells as
described below.
Lung tissue was harvested and fixed in 4% formalin for 24 h
followed by paraffin embedding for histological evaluation.
Assessment of T-cell subtypes (CD4
+, CD8
+) and
CD4+CD25+Foxp3
+ Tregs
Remaining erythrocytes in the cell suspension were treated with
erythrocyte lysis buffer (0.16 M NH4Cl, 11.9 M KHCO3 and
0.27 M ethylene diamine tetraacetic acid [EDTA]) for 15 min.
The leukocyte fraction was resuspended in PBS after washing
twice. Antibodies to detect CD4
+ (PE, BD Pharmingen, San
Diego, CA), CD8
+ (FITC, BD Pharmingen, San Diego, CA),
CD25
+ (PE-Cy7, BD Pharmingen, San Diego, CA) and FoxP3
+
(APC, eBioscience, Frankfurt, Germany) cells were used. Cells
were stained as previously described [21]. Intracellular staining of
forkhead box protein 3 (Foxp3), a well-established Treg marker, was
performed as described elsewhere [22]. A FACSCanto cytometer
(Becton Dickinson, Heidelberg, Germany) was used for detection.
Data analysis was carried out using FlowJo Software (Tree Star
Inc., Ashland, OR).
Assessment of plasma cytokine content
Cytometric Bead Array. Monocyte chemoattractant protein-1
(MCP-1), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a) and
interleukin-10 (IL-10) concentrations in plasma were determined
with cytometric bead arrays using the BD
TM CBA Mouse
Inflammation Kit (BD Pharmingen, San Diego, CA, USA)
according to the manufacturer’s instruction. In brief, 50 mlo f
mixed capture beads and 50 mL sample were incubated for 1 h
and after washing 50 ml Mouse Inflammation PE Detection Reagent was
added. After incubation for 1 h, complexes were washed and
analyzed using a FACSCalibur Cytometer (BD Biosciences,
Heidelberg, Germany). Data analysis was carried out using BD
CellQuest
TM Software.
Figure 2. Preparation of vital AFS cells and homogenized AFS cells. 10
6 vital AFS cells (vitAFS) were prepared in 0.7 ml sterile phosphate
buffered saline (PBS) for intraperitoneal injection in mice randomly assigned to the vitAFS group (2 h after LPS challenge). For the preparation of
homogenized AFS cells, 10
6 vital AFS cells underwent 5 min cell-disruption in 0.7 ml PBS prior to injection by sonication.
doi:10.1371/journal.pone.0035512.g002
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growth factor-beta (TGF-b) plasma levels were determined by
enzyme-linked immunosorbent assay (ELISA), using the
Platinum ELISA system precoated with primary antibodies
against IL-2 and TGF-b according to the manufacturer’s
instructions (eBioscience, Frankfurt, Germany). Briefly, Plasma
was diluted either 1:2 (IL-2) or 1:500 (TGF-b), applied to
precoated 96well-plates in duplicates and incubated with Biotin-
Conjugate for either 1 h (TGF-b) or 2 h (IL-2) at room
temperature. Wells were washed (56) and horseradish-
peroxidase-linked streptavidin was applied to all wells. After
incubation for 1 h, wells were washed (56) and the chromogen
3,39,5,59-Tetramethylbenzidine was applied for either 10 (IL-2) or
30 min (TGF-b). The chromogenic reaction was stopped by
adding sulfuric acid. Wells were read with a multiplate reader
(BioTek Synergy MX, Biotek, Bad Friedrichshall, Germany) at
450 nm. A standard dilution using standards with known protein
concentrations was included in the ELISA procedure to calculate
IL-2 and TGF-b plasma concentrations from an individual
standard curve.
Assessment of lung PMN infiltration
The lung PMN infiltration was determined by immunohisto-
chemical staining of paraffin embedded tissue sections with anti-
mouse Ly-6G primary antibody (BD Pharmingen, Heidelberg,
Germany). After microwave treatment in citrate buffer (10 mM
citric acid, pH 6.0) and inhibition of endogenous peroxidases with
3% hydrogen peroxidase (Merck, Darmstadt, Germany) sections
were incubated with the primary Ly-6G antibody for one hour.
Normal rabbit serum was used to avoid non-specific antibody
binding. After washing, a horseradish peroxidase (HRP)-conju-
gated antibody (Dako, Hamburg, Germany) was used as
secondary antibody. Immunostaining was developed by diamino-
benzidine (Dako, Hamburg, Germany) and slides were counter-
stained with Mayer’s haemalaum. For evaluation of the number of
infiltrating neutrophils, sections were blinded and randomized. Ly-
6G
+ neutrophils were counted in four representative, non-
overlapping high-power fields per section (Leica DM LB, Leica
Microsystems, Wetzlar, Germany).
Statistics
All statistical analyses were performed using Sigma-Stat
computer software (SPSS Inc., Chicago, IL, USA). We compared
groups using one-way analysis of variance (ANOVA) followed by
either Scheffe’s or Tukey’s post-hoc test for multiple comparison.
Differences were considered significant at a p-value of less than
0.05 and results are expressed as mean 6 standard error of the
mean (SEM).
Results
AFS cell culture
AFS cell characterization. Phenotypic FACS analysis
underlined that human AFS cells stably expressed CD29, CD44
(hyaluronate receptor), and stromal cell markers such as CD90
(Thy-1), CD105 (endoglin, TGF-b receptor), and CD73 at
different passages (analysis performed until passage 8). Human
AFS cells also expressed HLA-ABC but not HLA-DR, indicating
low immunogenicity profile. The expression of c-Kit was analyzed
at different passages by immunofluorescence showing that the
surface marker is internalized (present until passage 8),
importantlty SSEA-4 (stem cell embryonic antigen-4) was
consistently expressed (Figure 3).
AFS application
Plasma cytokine response 8 h after LPS challenge. Basal
IL-6 plasma concentrations of non-treated negative-controls were
not detectable and considered 0 pg/ml. 8 h after intraperitoneal
LPS injection (6 h after treatment with either vitAFS, homAFS, or
saline-treated positive-controls) IL-6 plasma levels were
significantly increased in all endotoxemic groups (range: 1546.89
to 5855.86 pg/ml) compared to negative-controls. Multi
comparison revealed no significant difference between positive-
controls and vitAFS or homAFS.
Plasma cytokine response 24 h after LPS
challenge. Negative-controls showed basal IL-6, TNF-a,
MCP-1 and IL-10 plasma concentrations of 0 pg/ml. Plasma
cytokine levels of the above mentioned cytokines/chemokines
were still altered 24 h after LPS injection compared to negative-
controls, but no significant difference was detected throughout the
two AFS-treated groups compared to the positive control as shown
in table 1. TGF-b plasma levels were not altered throughout the
groups (data not shown). The IL-2 plasma levels were significantly
increased in the group treated with homAFS compared to saline-
treated positive-controls (Figure 4).
Lymphocyte subpopulations. The percentage of
CD4
+CD25
+ lymphocytes expressing Foxp3
+ (Tregs) was
significantly increased in the group treated with homAFS
compared to saline-treated positive-controls and non-
endotoxemic negative-controls. Mice treated with vitAFS tended
to show similar regulations but the differences were not significant
(Figure 5). No changes in CD4
+ and CD8
+ lymphocyte
distribution were observed throughout the endotoxemic groups
compared to negative-controls 24 h after LPS challenge (data not
shown).
Pulmonary PMN infiltration. Pulmonary infiltration with
neutrophils was significantly increased in positive-controls
compared to negative-controls 24 h after LPS injection. In
contrast, homAFS application resulted in significantly decreased
pulmonary neutrophil infiltration compared to positive-controls.
No significant difference was found between homAFS-treated
mice compared to negative-controls. Again, vitAFS-treated
animals showed similar effects but statistical significance was not
reached (Figure 6).
HEK 293 T application
Plasma cytokine levels 24 h after LPS challenge. Parallel
to the findings in the AFS treatment group, elevations in plasma
cytokine levels of IL-6 (range 3.7 to 5.7 pg/ml), TNF-a (range
18.87 to 21.72 pg/ml) and MCP-1 (range 452.8 to 467.97 pg/ml)
were still present 24 h after LPS injection compared to negative-
controls. No relevant differences between the three endotoxemic
groups were detected between IL-6, TNF-a, MCP-1 and TGF-b
concentrations. The IL-2 plasma levels were significantly increased
in the group treated with vitHEK compared to saline-treated
positive-controls (Figure 7).
Lymphocyte subpopulations. Parallel to the findings after
application of homAFS cells, endotoxemic mice receiving vitHEK
showed a significant increase in the CD4
+CD25
+Foxp3
+
regulatory T-cell population compared to negative-controls,
endotoxemic saline-treated positive-controls as well as homHEK
treated mice. In contrast, no alterations were found in homHEK-
treated mice compared to controls (Figure 8). Distribution of
CD4
+ and CD8
+ lymphocytes was not altered in the endotoxemic
groups compared to negative-controls 24 h after LPS challenge
(data not shown).
Pulmonary PMN infiltration. 24 h after LPS injection,
pulmonary neutrophil infiltration was significantly increased in
Cellular Treatment during Sublethal Endotoxemia
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negative-controls. In contrast, mice injected with vitHEK
revealed decreased pulmonary neutrophil counts compared to
the two other endotoxemic groups (Figure 9).
Discussion
Modulation of inflammatory response by AFS cells
Tregs, a unique subset of CD4
+ lymphocytes, display potent
immunoregulatory functions in vitro and in vivo [23,24]. The
immunomodulatory potential of Tregs has been reported in
various studies of antigen-driven, T-cell-dependent adaptive but
also antigen-independent innate immune responses [25]. Research
for therapeutic implications is on-going. During infection and
inflammation Tregs play an ambivalent role by inhibiting anti-
microbial T effector cells and dampening immune responses [26]:
On the one hand clearance of microbial contamination requires
an appropriate immune reaction with significant effector cell
activity; on the other hand uncontrolled immune responses may
lead to distant organ damage, sepsis and multiple organ failure.
Several groups investigated the role of Tregs during inflammation
and sepsis. However, the exact molecular mechanisms, how Tregs
provide immunomodulatory properties, remain unclear.
Figure 3. Characterization of AFS cells by FACS analysis and Immunofluorescence. A. Representative histograms by fluorescence activated
cell sorter (FACS) analysis showing the expression of CD29, CD44, CD73,CD105, HLA-ABC and DR of AFS cells. The respective isotype control is shown
as a gray line. B. Representative immunofluorescence of AFS cells showing positive staining for c-kit and SSEA-4. Real magnification: 206.
doi:10.1371/journal.pone.0035512.g003
Figure 4. IL-2 plasma levels after AFS application. The IL-2
plasma levels were significantly increased in the group treated with
homAFS compared to saline-treated positive-controls (+).
doi:10.1371/journal.pone.0035512.g004
Table 1. Plasma cytokine response 24 h after LPS challenge
(AFS cells).
Control
(2) LPS
Saline (+) Vital AFS Hom. AFS
IL-6 [pg/ml] 0 9.9961.44* 12.6362.05* 12.2862.79*
TNF-a [pg/ml] 0 18.8861.05* 17.0860.93* 17.6561.3*
MCP-1[pg/ml] 0 448.94647.74* 498.1687.47* 416.39646.05*
IL-10 [pg/ml] 0 8.0961.26* 8.4860.83* 8.9961.65*
*p,0.05 vs. Control.
doi:10.1371/journal.pone.0035512.t001
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responses - including the activation of Tregs [7,8] - and eventually
provide potent anti-inflammatory properties during inflammation
and sepsis [4,7]. However, MSCs are rare in vivo, difficult to be
expanded in vitro, and malignant tumor formation could be related
to extensive passages in culture [13,27,28,29].
Amniotic fluid stem cells have been introduced as a relatively
new source of pluripotent stem cells. In contrast to MSCs, no
tumor formation has been reported using AFS cells even after
multiple passages [15]. The latter may be related to the fact that,
differently to AFS cells, MSCs do get exposed to viruses and toxic
agents during life [30].
Several possible applications in different models of disease have
been evaluated to date. However, the role of AFS cells during
inflammatory response remains unclear.
In our model of endotoxemia, application of homogenized AFS
cells significantly increased the population of CD4
+CD25
+Foxp3
+
regulatory T cells 24 h after endotoxemic challenge, whereas vital
AFS cells only tended to show these effects. These findings suggest
that similar to the effects reported in human MSCs, human AFS
cell application during early endotoxemia induces regulatory T
cell activity. Taken together, it is tempting to speculate that Treg-
inducing soluble factors are highly concentrated in the homoge-
nized AFS cell suspension after cell disruption and therefore
immediately available for Treg recruitment. In contrast, vital AFS
cells may provide a controlled release of these factors. Hence, a
significant effect of vital AFS cell application on Treg stimulation
could not be seen 24 h after LPS injection. However, parallel to
the immunosuppressive effects of human MSCs [7], the modula-
tions observed in the present study seem to be mainly controlled by
soluble factors. IL-2 and TGF-b are two cytokines well known for
their role in Treg induction and maintenance [24,26,32]. The
finding of increased IL-2 levels in those endotoxemic animals,
treated with homAFS cells suggests a prominent role of IL-2 for
Treg induction in this setting of sublethal endotoxemia, whereas
TGF-b does not seem to play a major role in our model. Due to
the complex regulations and numerous possible activation
pathways for Tregs [31] we believe, that one cannot attribute
the activation seen in our model to only one cytokine. The IL-2
pathway represents a major but not exclusive mechanism for the
development and function of Tregs [32]. Various factors (such as
human leucocyte antigen-G5 [HLA-G5], transforming growth factor-beta
[TGF-b], interleukin-2 [IL-2], prostaglandin E2 [PGE2], hepatocyte
growth factor [HGF], interleukin-10 [IL-10], galectin-3) but also cell-to-
cell interaction are held responsible for Treg induction [24,33]. To
date the exact molecular basis of Treg-activation remains unclear
and is the focus of on-going research [24].
Heuer et al. reported that adoptive transfer of Tregs has been
shown to improve survival and increase bacterial clearance in an
animal model of polymicrobial sepsis [34]. In a model of acute
lung injury D’Alessio et al. concluded that modulation of innate
immune responses is central to the Treg mediated coordination of
this response [23]. More recently, Venet et al. investigated the role
of Tregs during indirect acute lung injury in a model of
hemorrhagic shock followed by polymicrobial sepsis. The authors
described a central role of Tregs to the control of neutrophil
recruitment. Furthermore, they showed that specific down
regulation of Treg function (Foxp3 targeting siRNA) resulted in
increased pulmonary neutrophil recruitment and subsequent
organ damage [9].
In our model of sublethal endotoxemia increased pulmonary
neutrophil recruitment was observed in endotoxemic positive-
controls 24 h after LPS challenge. Application of homAFS cells
Figure 5. Percentage of regulatory T cells after AFS cell
application. The percentage of Foxp3
+ lymphocytes was significantly
increased in the pool of CD4
+CD25
+ lymphocytes after application of
homAFS compared to saline-treated positive-controls (+) and non-
endotoxemic negative-controls (2).
doi:10.1371/journal.pone.0035512.g005
Figure 6. Pulmonary PMN infiltration after AFS cell application.
Pulmonary infiltration with PMNs was significantly increased in positive-
controls (+) compared to negative-controls (2) 24 h after LPS injection.
Mice treated with hom AFS cells showed significantly decreased
pulmonary neutrophil influx compared to positive-controls (+).
doi:10.1371/journal.pone.0035512.g006
Figure 7. IL-2 plasma levels after HEK application. The IL-2
plasma levels were significantly increased in the group treated with
vitHEK compared to saline-treated positive-controls (+).
doi:10.1371/journal.pone.0035512.g007
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mic mice compared to positive-controls. The parallel finding of
increased Foxp3
+ Tregs supports the hypothesis that regulatory T
cells play a major role in mediating resolution of acute lung injury
[23].
Gonzales Rey et al. reported a significant decrease in
proinflammatory serum cytokines in mice suffering from polymi-
crobial sepsis for 18 h (CLP) and treated with human adipose
tissue derived stem cells (ASC) 4 h after sepsis induction. Similar
non-major histocompatibility complex (MHC)-restricted immuno-
modulations were reported by other groups [4,35,36]. In contrast
to these findings, we observed only minor changes in the
investigated systemic humoral immune responses after treatment
with both homogenized and vital AFS cells compared to saline
treatment 8 h and 24 h after sublethal LPS challenge. We chose a
model of sublethal endotoxemia to avoid uncontrolled immune
reactions. The present results suggest that AFS cells have no major
impact on the early cytokine release in our model of endotoxemia.
However, it remains unclear if or to what extent AFS cell
treatment is able to prevent/influence mortality in lethal models of
endotoxemia or polymicrobial sepsis. Furthermore, no changes in
CD4
+ CD8
+ subpopulations were observed, which is probably due
to the investigated time point. We assume that possible
immunomodulations of T-helper cell and cytotoxic T cell activity
might have a later onset.
In summary, application of AFS cells during LPS endotoxemia
modulates cellular immune responses and distant organ damage.
The observed immunomodulations are not dependent on viable
cells, suggesting a prominent role of soluble factors. One might
speculate that (once factors are identified and characterized)
cytokine therapy would be very attractive following these results,
but similarly to previous studies in other systems such as the heart
or the kidney it is difficult to mimic precisely the various molecules
and proteins secreted by the cells in that particular context
[20,37]. The cells/homogenates may therefore be necessary as
well in the clinical scenario. However, it is possible that established
cell lines could be used for therapy in various diseases. This
approach could be facilitated by the fact that in this context stem
cell engraftment does not usually persist with time and allogenic
derived cells could be used for therapy [38].
Immunomodulations are not exclusive attributes of stem
cells
Initially, the in vitro and in vivo immunosuppressive effect on
virtually all cells of the immune system has been exclusively
attributed to MSCs [18,39,40]. More recently, the exclusive role of
stem cells in cellular triggered immunomodulations has been
challenged by several authors, demonstrating that other cell types
like mature stromal cells (SCs) or renal tubular epithelial cells show
similar immunosuppressive properties and are able to modulate T-
cell responses and cytokine secretion in vitro [18,41]. Furthermore,
hepatic stellate cells have recently been reported to induce Foxp3
+
Tregs in a setting of co-transplantation with hepatocytes [42,43].
According to Jones et al. the observed effects required licensing of
SCs by cell-to-cell contact to produce soluble factors, which
ultimately mediate the immunosuppressive modulations [18].
In light of these findings we performed a second subset of
experiments using the non-stem cell line HEK 293 T in the above-
described model of endotoxemia instead of AFS cells. Interesting-
ly, Treg activation was also observed after treatment with vital
HEK, but not homogenized HEK cells. Parallel to these findings,
application of vital HEK cells resulted in significantly increased
IL-2 plasma levels and decreased pulmonary neutrophil infiltra-
tion compared to positive controls. Similar to the results observed
in AFS treated animals, no further relevant changes in plasma
cytokine concentrations or CD4
+ CD8
+ lymphocyte subpopula-
tions of HEK treated animals were found. Further studies are
needed to clarify the complex molecular background of the
observed phenomena and to evaluate the suppressive potential of
AFS and HEK on CD4
+/CD8
+ populations.
Our findings show that not only homogenized AFS cells but also
vital HEK cells modulate cellular immune response and distant
organ damage during endotoxemia. In the present study, viable
HEK cells are needed for the observed immunomodulations,
which is in line with the findings of Jones et al. [18]. Overall, these
findings support the hypothesis, that immunomodulations are not
exclusive attributes of stem cells.
Together with previous studies, the present study highlights the
increasing evidence that to date unidentified soluble factors seem
to be major contributors to the immunomodulations, previously
exclusively attributed to stem cells.
Figure 8. Percentage of regulatory T cells after HEK cell
application. Relative expression of Foxp3 in CD4
+CD25
+ lymphocytes
was significantly increased in the group treated with vitHEK cells
compared to endotoxemic mice, which received homHEK cells, saline-
treated positive-controls (+) and non-endotoxemic negative-controls
(2).
doi:10.1371/journal.pone.0035512.g008
Figure 9. Pulmonary PMN infiltration after HEK cell applica-
tion. Pulmonary infiltration with PMNs was significantly increased in
positive controls (+) and homHEK (p,0.05 vs. [2]) treated endotoxemic
mice compared to negative-controls (2) 24 h after LPS injection. Mice
treated with vitHEK cells showed significantly decreased pulmonary
neutrophil influx compared to positive-controls (+) and homHEK treated
endotoxemic mice.
doi:10.1371/journal.pone.0035512.g009
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Both AFS and HEK cells modulate cellular immune response
and distant organ damage during sublethal endotoxemia. The
observed effects cannot be exclusively attributed to AFS cells and
the immunomodulatory potency of cellular treatment seems to be
based on isolated factors.
However, the simultaneous findings of regulatory T-cell
activation and decreased pulmonary neutrophil influx suggest a
previously observed role of this T-cell subpopulation in controlling
neutrophil action during early inflammation. Further studies are
needed to evaluate molecular basis and therapeutic potential of
Treg activation during inflammatory response with regard to the
crucial balance between protection and pathology.
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